Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$2.43 +0.4%	$2.91	$2.06 ▼ $135.54	$7.01M	-0.32	175,317 shs	62,703 shs
ATNF 180 Life Sciences	$7.61 -28.9%	$2.15	$0.66 ▼ $17.75	$64.62M	0.38	23.48 million shs	26.49 million shs
SLRX Salarius Pharmaceuticals	$0.45 -6.4%	$0.77	$0.45 ▼ $7.20	$1.03M	0.45	6.25 million shs	577,955 shs
SXTP 60 Degrees Pharmaceuticals	$1.31 -3.0%	$1.92	$1.24 ▼ $12.70	$1.99M	2.71	225,749 shs	148,261 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+0.41%	+8.48%	-23.34%	-28.53%	-86.63%
ATNF 180 Life Sciences	-28.88%	+121.87%	+751.14%	+544.92%	+312.02%
SLRX Salarius Pharmaceuticals	-6.43%	-18.58%	-33.33%	-45.49%	-76.90%
SXTP 60 Degrees Pharmaceuticals	-2.96%	-0.76%	-25.14%	-46.96%	-80.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALZN Alzamend Neuro	3.0383 of 5 stars	3.5	2.0	2.9	3.3	0.6
ATNF 180 Life Sciences	0.5078 of 5 stars	0.0	2.0	3.0	1.7	0.0
SLRX Salarius Pharmaceuticals	0.2888 of 5 stars	0.0	2.0	3.5	0.0	0.0
SXTP 60 Degrees Pharmaceuticals	2.8268 of 5 stars	3.3	4.0	1.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	3.00	Buy	$180.00	7,307.41% Upside
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	0.00	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	2.50	Moderate Buy	$7.00	434.35% Upside

Current Analyst Ratings Breakdown

Latest SLRX, SXTP, ATNF, and ALZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/29/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/12/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
7/12/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/27/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/2/2025	SXTP 60 Degrees Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.80 ➝ $7.00
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$4.95 per share	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$0.89 per share	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	($0.39) per share	N/A
SXTP 60 Degrees Pharmaceuticals	$300K	6.42	N/A	N/A	($6.38) per share	-0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$4.51M	N/A	0.00	N/A	N/A	N/A	-181.34%	-116.84%	9/10/2025 (Estimated)
ATNF 180 Life Sciences	-$6.17M	-$15.07	N/A	∞	N/A	N/A	-141.25%	-80.77%	N/A
SLRX Salarius Pharmaceuticals	-$5.58M	-$4.82	N/A	∞	N/A	N/A	-556.47%	-192.35%	8/15/2025 (Estimated)
SXTP 60 Degrees Pharmaceuticals	-$7.95M	-$50.41	N/A	N/A	N/A	-976.86%	N/A	-122.33%	N/A

Latest SLRX, SXTP, ATNF, and ALZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2025	N/A	ALZN Alzamend Neuro	-$3.69	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	SXTP 60 Degrees Pharmaceuticals	-$1.24	-$1.25	-$0.01	-$1.25	$0.32 million	$0.31 million
8/12/2025	Q2 2025	SLRX Salarius Pharmaceuticals	-$2.20	-$0.45	+$1.75	-$0.45	N/A	N/A
7/23/2025	Q2 2025	ATNF 180 Life Sciences	N/A	-$0.30	N/A	-$0.30	N/A	N/A
5/15/2025	Q1 2025	ATNF 180 Life Sciences	N/A	-$0.67	N/A	-$0.67	N/A	N/A
5/15/2025	Q1 2025	SXTP 60 Degrees Pharmaceuticals	-$1.31	-$1.56	-$0.25	-$1.56	$0.15 million	$0.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	6.58	6.58
ATNF 180 Life Sciences	N/A	0.58	0.58
SLRX Salarius Pharmaceuticals	N/A	0.61	1.01
SXTP 60 Degrees Pharmaceuticals	N/A	3.14	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
ATNF 180 Life Sciences	4.07%
SLRX Salarius Pharmaceuticals	11.88%
SXTP 60 Degrees Pharmaceuticals	7.96%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	30.21%
ATNF 180 Life Sciences	38.20%
SLRX Salarius Pharmaceuticals	1.20%
SXTP 60 Degrees Pharmaceuticals	10.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	2.90 million	2.02 million	No Data
ATNF 180 Life Sciences	7	6.04 million	3.73 million	No Data
SLRX Salarius Pharmaceuticals	20	2.13 million	2.10 million	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	1.47 million	1.32 million	Not Optionable

SLRX, SXTP, ATNF, and ALZN Headlines

Recent News About These Companies

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

August 13 at 4:19 PM | globenewswire.com

60 Degrees Pharmaceuticals (SXTP) to Release Quarterly Earnings on Wednesday

August 12 at 2:11 AM | americanbankingnews.com

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

July 16, 2025 | globenewswire.com

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

July 15, 2025 | finanznachrichten.de

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration ...

July 15, 2025 | finanznachrichten.de

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

July 15, 2025 | globenewswire.com

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODAÂ® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

July 15, 2025 | globenewswire.com

SXTP - 60 Degrees Pharmaceuticals Inc Valuation - Morningstar

July 3, 2025 | morningstar.comM

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 Shares

June 6, 2025 | insidertrades.com

60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026

June 5, 2025 | nasdaq.com

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

June 4, 2025 | globenewswire.com

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

June 3, 2025 | globenewswire.com

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025 | globenewswire.com

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

April 22, 2025 | globenewswire.com

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

April 10, 2025 | insidermonkey.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

April 8, 2025 | globenewswire.com

60 Degrees Pharmaceuticals, Inc.

April 4, 2025 | uk.investing.com

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 21, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRX, SXTP, ATNF, and ALZN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$2.43 +0.01 (+0.41%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.38 -0.05 (-1.85%)

As of 08/14/2025 07:49 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

180 Life Sciences NASDAQ:ATNF

$7.61 -3.09 (-28.88%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.52 -0.09 (-1.13%)

As of 08/14/2025 07:59 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Salarius Pharmaceuticals NASDAQ:SLRX

$0.45 -0.03 (-6.43%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.45 0.00 (-1.04%)

As of 08/14/2025 07:59 PM Eastern

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$1.31 -0.04 (-2.96%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.33 +0.02 (+1.60%)

As of 08/14/2025 08:00 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time